Company Filing History:
Years Active: 1997
Title: The Innovations of Francis C. Zeigler
Introduction
Francis C. Zeigler is a notable inventor based in San Mateo, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of agonist antibodies.
Latest Patents
Zeigler holds a patent for "Agonist antibodies against the flk2/flt3 receptor and uses thereof." This patent describes agonist antibodies that bind to the extracellular domain of the flk2/flt3 receptor, activating its intracellular kinase domain. The labeled antibodies are useful as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells. These antibodies can cause primitive hematopoietic cells to proliferate and differentiate, enhancing the repopulation of mature blood cell lineages in mammals that have undergone chemotherapy, radiation therapy, or bone marrow transplantation. Additionally, these antibodies are beneficial for treating mammals that have experienced a decrease in blood cells due to disease or hemorrhage.
Career Highlights
Francis C. Zeigler is associated with Genentech, Inc., a leading biotechnology company known for its innovative therapies. His work has contributed to advancements in medical treatments and diagnostics.
Collaborations
Some of his notable coworkers include Brian Drake Bennett and Susan D. Broz, who have collaborated with him on various projects within the field.
Conclusion
Francis C. Zeigler's contributions to biotechnology through his patent on agonist antibodies highlight his role as an influential inventor. His work continues to impact the medical field positively.